Boardroom Alpha
Boardroom Alpha
PHIO · Additional Proxy Materials (DEFA14A) · Filed August 14, 2026

Phio Pharmaceuticals Corp — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
August 14, 2026
Ticker
PHIO
Accession
0001683168-26-006474
Boardroom Alpha · Filing insights

Phio Pharmaceuticals' board urges votes FOR all director nominees and for Proposals 2 and 3.

About Phio Pharmaceuticals Corp
Market cap
$14M
1Y TSR
−49.9%
3Y TSR
−62.8%
Board grade
D
Sector
Healthcare
CEO
Robert J Bitterman
Last annual meeting: Sep 28, 2026 · View full Phio Pharmaceuticals Corp profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Filed by the Registrant ☒

 

Filed by a Party other than the Registrant ☐

 

Check the appropriate box:

 

  Preliminary Proxy Statement
   
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
     
  Definitive Proxy Statement
   
  Definitive Additional Materials
   
  Soliciting Material under §240.14a-12

 

PHIO PHARMACEUTICALS CORP.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

  No fee required.
   
  Fee paid previously with preliminary materials.
   
  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

   

 

 

www.investorvote.com/PHIO Easy Online Access — View your proxy materials and vote. Step 1: Step 2: Step 3: Step 4: Step 5: Go to www.investorvote.com/PHIO. Click on the icon on the right to view meeting materials. Return to the investorvote.com window and follow the instructions on the screen to log in. Make your selections as instructed on each screen for your delivery preferences. Vote your shares. Online Go to www.investorvote.com/PHIO or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 1234 5678 9012 345 Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on September 28, 2026. Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2026 proxy statement and 2025 annual report to shareholders are available at: 04BF6D When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before September 14, 2026 to facilitate timely delivery. 2 N O T MMMMMMMMMMMM MMMMMMMMM 000001 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE SACKPACK C 1234567890 C O Y MMMMMMM

 
 

Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/PHIO. — Phone – Call us free of charge at 1 - 866 - 641 - 4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials Phio Pharmaceuticals Corp.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by September 14, 2026. Stockholder Meeting Notice Dear Phio Pharmaceuticals Corp. Stockholder, The 2026 Annual Meeting of Stockholders of Phio Pharmaceuticals Corp. will be held on September 28, 2026 at 9:00 a.m. Eastern Time, virtually via the internet at meetnow.global/MFT9CLT. To access the virtual meeting, you must have the 15 - digit code that is printed in the shaded bar located on the reverse side of this form. You are receiving this communication because you owned shares of the Company on August 4, 2026, the record date, which entitles you to vote at the Annual Stockholder Meeting. Proxy materials are now available on the Internet. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all nominees and FOR Proposals 2 and 3: 1. Election of Directors: 01 - Robert J . Bitterman 02 - Patricia A . Bradford 03 - David H . Deming 04 - Jonathan E . Freeman, Ph . D . 05 - Curtis A . Lockshin, Ph . D . 06 - R . Todd Plott, M . D . 2. The ratification of Grant Thornton, LLP as our independent registered public accounting firm for the fiscal year ending December 31 , 2026 . 3. Approval of an amendment to the 2020 Phio Pharmaceuticals Corp . Long Term Incentive Plan, as amended and restated, to increase the number of shares of common stock available for issuance thereunder by 1 , 500 , 000 . PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card.

 
 

 

You invested in PHIO PHARMACEUTICALS CORP and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on September 28, 2026. Get informed before you vote View the Annual Report, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 14, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID - JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 1 OF 322,224 148,294 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX PHIO PHARMACEUTICALS CORP 2026 Annual Meeting Vote by September 27, 2026 11:59 PM ET Vote in Person at the Meeting* September 28, 2026 9:00 AM EDT Virtually via the internet at: meetnow.global/MFT9CLT To access the virtual meeting, you must refer to the "General Information" section of the proxy statement.

 
 

Voting Items Board Recommends For 1. Election of Directors Nominees: 1A Robert J. Bitterman For Patricia A. Bradford 1B For David H. Deming 1C For Jonathan E. Freeman PhD 1D For Curtis A. Lockshin PhD 1E For R. Todd Plott, M.D. 1F For 2. The ratification of Grant Thornton, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. Approval of an amendment to the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, as amended and restated, to increase the number of shares of common stock available for issuance thereunder by 1,500,000. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID - JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting . We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date . PHIO PHARMACEUTICALS CORP 2026 Annual Meeting Vote by September 27, 2026 11:59 PM ET

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Phio Pharmaceuticals Corp (PHIO)

Reference

Frequently asked questions

When did Phio Pharmaceuticals Corp file this DEFA14A?
Phio Pharmaceuticals Corp (PHIO) filed this Additional Proxy Materials (DEFA14A) with the SEC on August 14, 2026. The accession number assigned by EDGAR is 0001683168-26-006474.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Phio Pharmaceuticals' board urges votes FOR all director nominees and for Proposals 2 and 3. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Phio Pharmaceuticals Corp's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Phio Pharmaceuticals Corp has filed under CIK 1533040, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer